These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38876305)

  • 1. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
    Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S
    J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The In Situ Structure of Parkinson's Disease-Linked LRRK2.
    Watanabe R; Buschauer R; Böhning J; Audagnotto M; Lasker K; Lu TW; Boassa D; Taylor S; Villa E
    Cell; 2020 Sep; 182(6):1508-1518.e16. PubMed ID: 32783917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.
    Madero-Pérez J; Fdez E; Fernández B; Lara Ordóñez AJ; Blanca Ramírez M; Gómez-Suaga P; Waschbüsch D; Lobbestael E; Baekelandt V; Nairn AC; Ruiz-Martínez J; Aiastui A; López de Munain A; Lis P; Comptdaer T; Taymans JM; Chartier-Harlin MC; Beilina A; Gonnelli A; Cookson MR; Greggio E; Hilfiker S
    Mol Neurodegener; 2018 Jan; 13(1):3. PubMed ID: 29357897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 and Rab GTPases.
    Pfeffer SR
    Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
    Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
    J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson's disease-linked LRRK2 kinase.
    Dhekne HS; Tonelli F; Yeshaw WM; Chiang CY; Limouse C; Jaimon E; Purlyte E; Alessi DR; Pfeffer SR
    Elife; 2023 Oct; 12():. PubMed ID: 37874635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of phospho-specific Rab protein antibodies to monitor
    Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
    Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-Rich Repeat Kinases.
    Alessi DR; Pfeffer SR
    Annu Rev Biochem; 2024 Aug; 93(1):261-287. PubMed ID: 38621236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease.
    Tezuka T; Ishiguro M; Taniguchi D; Osogaguchi E; Shiba-Fukushima K; Ogata J; Ishii R; Ikeda A; Li Y; Yoshino H; Matsui T; Kaida K; Funayama M; Nishioka K; Kumazawa F; Matsubara T; Tsuda H; Saito Y; Murayama S; Imai Y; Hattori N
    Neurobiol Dis; 2024 Sep; 199():106571. PubMed ID: 38901781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.